CD19 Inhibitor Shows Promise in Non-Hodgkin Lymphoma

Article

A novel inhibitor of CD19 was well tolerated and showed promising activity in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma, according to a phase I study.

Diffuse large B-cell lymphoma

CSF cytology of a diffuse large B-cell lymphoma; source: Jensflorian, Wikimedia Commons

A novel inhibitor of CD19 was well tolerated and showed promising activity in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL), according to a phase I study. Results were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Andres Forero-Torres, MD, of the University of Alabama at Birmingham, presented the study and said that new treatment approaches are still urgently needed in this patient population. About 40% of relapsed/refractory NHL patients do not respond to salvage therapy, and around 80% don’t respond to third-line treatment following salvage therapy and have an overall survival of only about 4 months.

SGN-CD19A is a humanized anti-CD19 monoclonal antibody, and clinical activity has been seen in other trials of patients with acute lymphoblastic leukemia. CD19 is the most widely expressed antigen in B-cell malignancies.

The new phase I trial was  an open-label dose escalation study with 7 different dose levels. No dose-limiting toxicities have yet been found, and the 3, 4, and 5 mg/kg dose cohorts have been expanded. The initial cohort was 59% male with a median age of 65 years. Most patients included had diffuse large B-cell lymphoma (86%), while 11% had mantle cell lymphoma and 3% had grade 3 follicular lymphoma.

Out of the total study group of 37 patients, there were six complete responses (16%) and five partial responses (14%) for a total objective response rate of 30%. Three of the complete responses came at the 4 mg/kg dose and one each at 1, 2, and 3 mg/kg doses. There were two partial responses at 6 mg/kg, 2 at 5 mg/kg, and 1 at 4 mg/kg. Progressive disease (35% of patients) was spread across the dose levels.

Most adverse events were grades 1 and 2. Grade 3 or higher adverse events seen in at least two patients included blurred vision, keratopathy, thrombocytopenia, and anemia.

Vision problems were generally a notable characteristic of therapy with this drug, with 84% of patients experiencing some eye event. Two patients (5%) discontinued treatment as a result, and five (14%) had dose delay or reduction. Most of these resolved with treatment or were downgraded to grade 1 or 2, and Forero-Torres said the impact of steroid prophylaxis is under evaluation.

“Preclinical data demonstrate synergy with relevant standard of care agents,” Forero-Torres said. “Encouraging antitumor activity with manageable toxicities enables novel combination regimens.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content